KLRS Kalaris Therapeutics, Inc. - Common Stock
NASDAQ · Biotechnology · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 11, 2026
$2.70
· of 52w range
· above low
· to high
$2.5152w low
$11.5552w high
Market Cap (MRQ)
$64M
P/E
-0.9
EPS
$-2.85
your badges
52W Range
$3–$12
Analyst Rating
STRONG BUY
Price Target
$19
P/E
-0.9
ROE
-65.8%
Net Profit Margin
·
Your badge strip is empty — pin a metric anywhere on this page.
KLRS Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$2.70
Market Cap (MRQ)
$64M
P/E
-0.9
EPS
$-2.85
ROE
-65.8%
52W Range
$3–$12
KLRS Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
Stock splits
| Ex-date | Split | Type |
|---|---|---|
| Jan. 16, 2025 | 1-for-23 | Reverse |
10-Year Performance Revenue, net income, margins and EPS trends
Revenue·2019-12-31 → 2019-12-31
EPS$-2.852021-12-31 → 2025-12-31
Free Cash Flow$-39M2020-12-31 → 2025-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | KLRS | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E | -0.95Y avg ≈-33.2 | ≈-33.2 | · | · | |
| P/B (MRQ) | 1.15Y avg ≈16.0 | ≈16.0 | 1.3 | Pricier | |
| Price / FCF | -1.6 | · | · | · | |
| Price / Cash Flow | -1.65Y avg ≈-24.4 | ≈-24.4 | · | · | |
| Price / Tangible Book | 0.85Y avg ≈45.1 | ≈45.1 | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | KLRS | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| ROA | -67.9%5Y avg ≈-61.8% | ≈-61.8% | -69.2% | In line | |
| ROE | -65.8%5Y avg ≈-184.8% | ≈-184.8% | -72.9% | In line | |
| ROIC | -58.6%5Y avg ≈-82.4% | ≈-82.4% | -70.9% | Top tier |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | KLRS | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 11.05Y avg ≈12.9 | ≈12.9 | 3.3 | Strong liquidity | |
| Quick Ratio | 12.15Y avg ≈12.7 | ≈12.7 | 3.2 | Strong liquidity | |
| Interest Coverage | -32.0 | · | -32.0 | In line |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-21.7%
Next Report
Nov 10, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 19, 2026 | $-0.48 | $-0.50 | 4.9% |
| March 31, 2026 | May 20, 2026 | $-0.46 | $-0.53 | 13.8% |
| Dec. 31, 2025 | $-0.51 | $-0.54 | 5.9% | |
| Sept. 30, 2025 | $-0.64 | $-0.67 | 3.9% | |
| June 30, 2025 | $-0.61 | $-0.53 | -15.0% | |
| March 31, 2025 | $-2.52 | $-0.79 | -218.8% | |
| June 30, 2024 | $-1.15 | $-2.46 | 53.3% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | · | · | · | · | $165.0K | |
| R&D Expense | $31M | $45M | $133M | $119M | $121M | $50M | $16M | |
| SG&A Expense | $15M | $7M | $48M | $52M | $49M | $22M | $11M | |
| Operating Expenses | $46M | $52M | $200M | $171M | $170M | $71M | $27M | |
| Operating Income | $-46M | $-52M | $-200M | $-171M | $-170M | $-71M | $-27M | |
| Interest Expense | $1M | $3M | · | · | · | · | · | |
| Interest Income | · | $5M | $6M | $2M | $1M | $1M | $2M | |
| Other Non-op | $3M | $188.0K | $4M | $351.0K | $-2M | $195.0K | $797.0K | |
| Pretax Income | $-43M | $-69M | $-191M | $-169M | $-171M | $-70M | $-24M | |
| Income Tax | $0 | $0 | $-126.0K | $-265.0K | $1M | · | · | |
| Net Income | $-43M | $-69M | $-190M | $-169M | $-172M | $-70M | $-24M | |
| EPS (Basic) | $-2.85 | $-51.77 | $-42.09 | $-2.20 | $-2.74 | · | · | |
| EPS (Diluted) | $-2.85 | $-51.77 | $-42.09 | $-2.20 | $-2.74 | · | · | |
| Shares (Basic) | 15,267,817 | 1,335,925 | 4,524,226 | 76,654,856 | 62,782,126 | · | · | |
| Shares (Diluted) | 15,267,817 | 1,335,925 | 4,524,226 | 76,654,856 | 62,782,126 | · | · | |
| EBITDA | $-46M | $-65M | $-200M | $-170M | · | $-71M | · |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $98M | $2M | $90M | $106M | $202M | $123M | $61M | |
| Short-term Investments | $20M | $0 | $94M | $128M | $46M | $234M | $65M | |
| Prepaid Expense | $827.0K | $967.0K | $3M | $7M | $5M | $5M | $676.0K | |
| Current Assets | $119M | $3M | $188M | $243M | $253M | $361M | $127M | |
| PP&E (Net) | · | · | · | $930.0K | $2M | $812.0K | $350.0K | |
| PP&E (Gross) | · | · | $2M | $2M | $2M | $904.0K | $369.0K | |
| Accum. Depreciation | · | · | · | $1M | $281.0K | $92.0K | $19.0K | |
| Other Non-current Assets | $953.0K | $410.0K | $122.0K | $612.0K | $1M | · | · | |
| Total Assets | $122M | $6M | $191M | $277M | $287M | $371M | $139M | |
| Accounts Payable | $1M | $2M | $7M | $3M | $8M | $963.0K | $630.0K | |
| Accrued Liabilities | · | $5M | $10M | $14M | $20M | $8M | $5M | |
| Current Liabilities | $10M | $25M | $28M | $24M | $38M | $12M | $9M | |
| Capital Leases | $1M | $0 | $17M | $28M | $23M | $5M | $9M | |
| Total Liabilities | $43M | $57M | $45M | $53M | $61M | $18M | $18M | |
| Common Stock | $2.0K | $0 | $0 | $9.0K | $7.0K | $7.0K | · | |
| Paid-in Capital | $239M | $20M | $802M | $691M | $522M | $478M | $4M | |
| Retained Earnings | $-160M | $-117M | $-656M | $-466M | $-297M | $-125M | $-55M | |
| AOCI | $6.0K | $0 | $-62.0K | $-468.0K | $-155.0K | $-112.0K | $68.0K | |
| Stockholders' Equity | $79M | $-97M | $-45M | $225M | $225M | $353M | $-52M | |
| Liabilities + Equity | $122M | $6M | $191M | $277M | $287M | $371M | $139M | |
| Shares Outstanding | 22,902,418 | 1,356,431 | 4,962,997 | 93,093,243 | 63,565,886 | 61,931,255 | 2,099,740 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| D&A | · | · | $398.0K | $723.0K | $189.0K | $73.0K | $19.0K | |
| Stock-based Comp | $2M | $895.0K | $41M | $41M | $44M | $9M | $3M | |
| Deferred Tax | $0 | $0 | · | · | · | · | · | |
| Restructuring | · | $10M | · | · | · | · | · | |
| Other Non-cash | · | · | $25M | $-15M | · | $-529.0K | · | |
| Operating Cash Flow | $-38M | $-21M | $-124M | $-142M | $-106M | $-61M | $-20M | |
| CapEx | $200.0K | · | · | · | $26.0K | $235.0K | $339.0K | |
| Investing Cash Flow | $-20M | $95M | $38M | $-80M | $186M | $-169M | $-65M | |
| Stock Issued | $42M | · | · | $126M | · | · | · | |
| Net Stock Activity | $42M | · | · | $126M | · | · | · | |
| Financing Cash Flow | $155M | $19M | $70M | $127M | $232.0K | $292M | $121M | |
| Net Change in Cash | $97M | $-2M | $-16M | $-96M | $80M | $62M | $36M | |
| Taxes Paid | $0 | $0 | $220.0K | $613.0K | · | · | · | |
| Free Cash Flow | $-39M | · | · | · | · | $-61M | · | |
| Levered FCF | $-40M | · | · | · | · | · | · |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| ROA | -67.9% | -38.0% | -81.4% | -59.9% | · | -27.4% | · | |
| ROE | -65.8% | -491.2% | -111.6% | -70.6% | · | -19.2% | · | |
| ROIC | -58.6% | -57.8% | -137.0% | -76.1% | · | · | · |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 12.2 | 22.6 | 6.6 | 10.0 | · | 29.4 | · | |
| Quick Ratio | 12.1 | 22.6 | 6.5 | 9.6 | · | 29.0 | · | |
| Interest Coverage | -32.0 | · | · | · | · | · | · |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $3.44 | $22.48 | $1.28 | $2.41 | · | $5.70 | · | |
| Cash Flow / Share | $-2.51 | $-13.52 | $-1.20 | $-1.85 | · | · | · | |
| Cash / Share | $4.28 | $23.47 | $0.79 | $1.14 | · | $1.98 | · | |
| EPS (TTM) | $-2.85 | $-51.77 | $-42.09 | $-2.20 | $-2.74 | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-43M | $-69M | $-190M | $-169M | $-172M | $-70M | · | |
| Market Cap | $193M | $49M | $1.79B | $10.98B | · | $54.75B | · | |
| P/E | -3.0 | -0.2 | -0.4 | -53.6 | -108.6 | · | · | |
| P/B | 2.5 | 0.4 | 12.2 | 48.9 | · | 155.1 | · | |
| P / Tangible Book | 2.5 | · | · | 48.9 | 84.0 | 155.1 | · | |
| P / Cash Flow | -5.0 | -0.7 | -14.3 | -77.3 | · | -900.4 | · | |
| P / FCF | -5.0 | · | · | · | · | -896.9 | · | |
| Earnings Yield | -33.8% | -535.9% | -269.1% | -1.9% | -0.92% | · | · |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $9M | $8M | $7M | $9M | $8M | $6M | $4M | $36M | $3M | $2M | $33M | $34M | $35M | $31M | $28M | $30M | |
| SG&A Expense | $3M | $4M | $4M | $4M | $4M | $4M | $3M | $2M | $976.0K | $602.0K | $10M | $13M | $12M | $13M | $12M | $13M | |
| Operating Expenses | $12M | $12M | $11M | $13M | $12M | $10M | $7M | $38M | $4M | $3M | $62M | $47M | $47M | $43M | $40M | $43M | |
| Operating Income | $-12M | $-12M | $-11M | $-13M | $-12M | $-10M | $-7M | $-38M | $-4M | $-3M | $-62M | $-47M | $-47M | $-43M | $-40M | $-43M | |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1M | $1M | $815.0K | $499.0K | $78.0K | · | · | · | · | · | · | |
| Interest Income | · | · | · | · | · | · | · | $1M | $1M | $1M | $1M | $2M | $2M | $1M | $898.0K | $668.0K | |
| Other Non-op | $871.0K | $977.0K | $803.0K | $847.0K | $906.0K | $193.0K | $64.0K | $31.0K | $66.0K | $27.0K | $1M | $1M | $521.0K | $723.0K | $986.0K | $210.0K | |
| Pretax Income | · | · | · | · | · | · | · | · | · | · | $-60M | $-44M | $-45M | · | $-39M | $-42M | |
| Income Tax | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $-126.0K | $0 | $0 | $0 | $-415.0K | $0 | |
| Net Income | $-12M | $-11M | $-10M | $-12M | $-11M | $-10M | $-22M | $-38M | $-6M | $-3M | $-60M | $-44M | $-45M | $-41M | $-38M | $-42M | |
| EPS (Basic) | $-0.48 | $-0.46 | $0.92 | $-0.64 | $-0.61 | $-2.52 | $-16.75 | $-28.16 | $-4.26 | $-2.60 | $-40.78 | $-0.39 | $-0.48 | $-0.44 | $-0.32 | $-0.50 | |
| EPS (Diluted) | $-0.48 | $-0.46 | $0.92 | $-0.64 | $-0.61 | $-2.52 | $-16.75 | $-28.16 | $-4.26 | $-2.60 | $-40.78 | $-0.39 | $-0.48 | $-0.44 | $-0.32 | $-0.50 | |
| Shares (Basic) | 23,797,306 | 23,723,618 | · | 18,701,708 | 18,701,286 | 4,053,140 | · | 1,352,265 | 1,325,706 | 1,312,552 | · | 113,894,188 | 94,625,837 | 93,303,672 | · | 84,948,837 | |
| Shares (Diluted) | 23,797,306 | 23,723,618 | · | 18,701,708 | 18,701,286 | 4,053,140 | · | 1,352,265 | 1,325,706 | 1,312,552 | · | 113,894,188 | 94,625,837 | 93,303,672 | · | 84,948,837 | |
| EBITDA | $-12M | $-12M | · | $-13M | $-12M | $-10M | · | $-6M | $-8M | $-32M | · | $-47M | $-47M | $-43M | · | $-43M |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $43M | $34M | $98M | $42M | $88M | $101M | $2M | $117M | $105M | $86M | $90M | $96M | $197M | $116M | $106M | $124M | |
| Short-term Investments | $50M | $63M | $20M | $35M | · | · | $0 | $5M | $25M | $54M | $94M | $118M | $50M | $87M | $128M | $140M | |
| Prepaid Expense | $2M | $861.0K | $827.0K | $1M | $3M | $1M | $967.0K | $626.0K | $230.0K | $771.0K | $3M | $6M | $5M | $7M | $7M | $6M | |
| Current Assets | $96M | $98M | $119M | $78M | $92M | $102M | $3M | $123M | $130M | $141M | $188M | $220M | $253M | $212M | $243M | $272M | |
| PP&E (Net) | · | · | · | · | · | · | · | · | · | · | · | $673.0K | $759.0K | $844.0K | $930.0K | $943.0K | |
| PP&E (Gross) | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $2M | · | |
| Other Non-current Assets | $2M | $2M | $953.0K | $976.0K | $691.0K | $410.0K | $410.0K | · | · | · | $122.0K | $1M | $684.0K | $490.0K | $612.0K | $734.0K | |
| Total Assets | $100M | $110M | $122M | $81M | $93M | $103M | $6M | $123M | $131M | $144M | $191M | $248M | $283M | $244M | $277M | $294M | |
| Accounts Payable | $1M | $905.0K | $1M | $494.0K | $4M | $2M | $2M | $51.0K | $110.0K | $765.0K | $7M | $4M | $5M | $4M | $3M | $5M | |
| Accrued Liabilities | · | · | · | · | · | · | · | $1M | $2M | $5M | $10M | $16M | $17M | $12M | $14M | $14M | |
| Current Liabilities | $9M | $8M | $10M | $6M | $8M | $7M | $25M | $1M | $2M | $8M | $28M | $33M | $31M | $25M | $24M | $21M | |
| Capital Leases | $1M | $1M | $1M | $1M | · | · | $0 | · | $8M | $16M | $17M | $20M | $23M | $26M | $28M | $20M | |
| Total Liabilities | $42M | $41M | $43M | $39M | $40M | $39M | $57M | $1M | $11M | $24M | $45M | $53M | $54M | $51M | $53M | $40M | |
| Common Stock | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $0 | $11.0K | $11.0K | $11.0K | $0 | $11.0K | $11.0K | $9.0K | $9.0K | $9.0K | |
| Paid-in Capital | $240M | $239M | $239M | $192M | $191M | $191M | $20M | $818M | $813M | $807M | $802M | $792M | $782M | $701M | $691M | $681M | |
| Retained Earnings | $-182M | $-171M | $-160M | $-150M | $-138M | $-127M | $-117M | $-697M | $-693M | $-686M | $-656M | $-596M | $-552M | $-507M | $-466M | $-428M | |
| AOCI | $-73.0K | $-49.0K | $6.0K | $6.0K | · | · | $0 | $-134.0K | $-139.0K | $-138.0K | $-62.0K | $-200.0K | $-225.0K | $-301.0K | $-468.0K | $-563.0K | |
| Stockholders' Equity | $58M | $69M | $79M | $42M | $53M | $64M | $-97M | $121M | $120M | $120M | $146M | $195M | $229M | $194M | $225M | $253M | |
| Liabilities + Equity | $100M | $110M | $122M | $81M | $93M | $103M | $6M | $123M | $131M | $144M | $191M | $248M | $283M | $244M | $277M | $294M | |
| Shares Outstanding | 23,804,981 | 22,992,291 | 22,902,418 | 18,702,418 | 18,702,418 | 18,702,418 | 1,356,431 | 115,438,119 | 115,312,411 | 114,881,765 | 4,962,997 | 113,966,594 | 113,716,018 | 93,427,990 | 93,093,243 | 92,640,109 |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | · | · | · | $141.0K | $86.0K | $85.0K | $86.0K | $86.0K | $85.0K | |
| Stock-based Comp | $644.0K | $580.0K | $333.0K | $638.0K | $591.0K | $374.0K | $280.0K | $-10M | $-5M | $31.0K | $10M | $10M | $10M | $10M | $9M | $11M | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | $0 | |
| Restructuring | · | · | · | · | · | · | · | $100.0K | $500.0K | $10M | · | · | · | · | · | · | |
| Other Non-cash | · | · | · | · | · | · | · | · | · | · | · | · | · | $-1M | · | · | |
| Operating Cash Flow | $-11M | $-12M | $-7M | $-11M | $-13M | $-7M | $-8M | $43M | $36M | $-5M | $-31M | $-34M | $-27M | $-32M | $-32M | $-35M | |
| CapEx | · | · | $17.0K | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Investing Cash Flow | $20M | $-50M | $15M | · | · | · | · | $20M | $30M | $40M | $25M | $-67M | $38M | $42M | $14M | $-39M | |
| Stock Issued | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | |
| Financing Cash Flow | $-377.0K | $-2M | $48M | $0 | $0 | $107M | $8M | $12M | $5M | $7M | $11.0K | $0 | · | · | $292.0K | $126M | |
| Net Change in Cash | $9M | $-64M | $56M | $-46M | $-13M | $100M | $-274.0K | $-16M | $7M | $2M | $-6M | $-101M | $81M | $10M | $-18M | $53M | |
| Taxes Paid | · | · | · | · | · | · | · | · | · | · | $-131.0K | $1.0K | · | · | $-390.0K | $0 |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -12.0% | -10.2% | · | -11.7% | -10.1% | -8.2% | · | -2.2% | -2.9% | -15.6% | · | -16.3% | -18.8% | -17.3% | · | -13.8% | |
| ROE | -20.8% | -16.4% | · | -14.6% | -13.1% | -11.1% | · | -2.6% | -3.5% | -19.3% | · | -19.7% | -23.4% | -21.4% | · | -16.2% | |
| ROIC | · | · | · | · | · | · | · | · | · | · | · | -24.0% | -20.6% | · | · | · |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.0 | 12.2 | · | 12.9 | 12.0 | 14.3 | · | 86.8 | 55.1 | 18.5 | · | 6.7 | 8.3 | 8.5 | · | 13.1 | |
| Quick Ratio | 10.7 | 12.0 | · | 12.7 | 11.6 | 14.1 | · | 86.3 | 54.9 | 18.4 | · | 6.5 | 8.1 | 8.1 | · | 12.7 | |
| Interest Coverage | · | · | · | · | · | -7.2 | · | · | · | · | · | · | · | · | · | · |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $2.42 | $2.98 | · | $2.24 | $2.84 | $3.42 | · | $1.05 | $1.04 | $1.05 | · | $1.71 | $2.01 | $2.07 | · | $2.73 | |
| Cash Flow / Share | · | $-0.49 | · | · | · | $-1.84 | · | · | · | $-0.39 | · | · | · | $-0.34 | · | · | |
| Cash / Share | $1.81 | $1.50 | · | $2.27 | $4.73 | $5.40 | · | $1.01 | $0.91 | $0.75 | · | $0.84 | $1.73 | $1.24 | · | $1.34 | |
| EPS (TTM) | $-0.66 | $-0.79 | · | $-20.52 | $-48.04 | $-51.69 | · | $-75.80 | $-48.03 | $-44.25 | · | $-1.63 | $-1.74 | $-1.95 | · | $-2.80 |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-44M | $-44M | · | $-55M | $-82M | $-76M | · | $-107M | $-113M | $-153M | · | $-169M | $-167M | $-166M | · | $-189M | |
| Market Cap | $97M | $133M | · | $108M | $50M | $150M | · | $2.15B | $1.92B | $1.99B | · | $5.64B | $8.89B | $8.47B | · | $16.81B | |
| P/E | -6.2 | -7.3 | · | -0.3 | -0.1 | -0.2 | · | -0.2 | -0.3 | -0.4 | · | -30.3 | -44.9 | -46.5 | · | -64.8 | |
| P/B | 1.7 | 1.9 | · | 2.6 | 0.9 | 2.4 | · | 17.7 | 15.9 | 16.6 | · | 28.9 | 38.8 | 43.7 | · | 66.4 | |
| P / Tangible Book | 1.7 | 1.9 | · | 2.6 | 0.9 | 2.4 | · | 17.7 | 15.9 | 16.6 | · | 28.9 | 38.8 | 43.7 | · | 66.4 | |
| P / Cash Flow | · | -11.5 | · | · | · | -20.2 | · | · | · | -45.0 | · | · | · | -263.6 | · | · | |
| Earnings Yield | -16.2% | -13.7% | · | -355.0% | -1799.2% | -643.7% | · | -407.4% | -288.8% | -254.8% | · | -3.3% | -2.2% | -2.1% | · | -1.5% |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Net Income | $-43M | $-69M | $-190M | $-169M | $-172M |
| Diluted EPS | $-2.85 | $-51.77 | $-42.09 | $-2.20 | $-2.74 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Current Ratio | 12.2 | 22.6 | 6.6 | 10.0 | · |
| Quick Ratio | 12.1 | 22.6 | 6.5 | 9.6 | · |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | $-39M | · | · | · | · |
Institutional owners (13F) 57 filers · $75.8M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
57
Value held
$75.8M
New positions
9
Exited positions
11
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 9 (-6 vs prior Q) | 11 (+4 vs prior Q) | 18 (+2 vs prior Q) | 9 (+2 vs prior Q) | -548K |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| SAMSARA BIOCAPITAL, LLC | $52,426,382 | 12,881,175 | 69.20% | Shares |
| RTW INVESTMENTS, LP | $5,291,000 | 1,300,000 | 6.98% | Shares |
| VANGUARD GROUP INC | $2,471,147 | 292,790 | 3.26% | Shares |
| Alyeska Investment Group, L.P. | $2,330,836 | 572,687 | 3.08% | Shares |
| Siren, L.L.C. | $1,773,698 | 435,798 | 2.34% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $1,622,758 | 398,712 | 2.14% | Shares |
| Ikarian Capital, LLC | $1,465,201 | 360,000 | 1.93% | Shares |
| UBS Group AG | $1,066,873 | 262,131 | 1.41% | Shares |
| RENAISSANCE TECHNOLOGIES LLC | $607,859 | 149,351 | 0.80% | Shares |
| MARSHALL WACE, LLP | $566,549 | 139,201 | 0.75% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $464,287 | 114,037 | 0.61% | Shares |
| Woodline Partners LP | $407,000 | 100,000 | 0.54% | Shares |
| ADAR1 Capital Management, LLC | $407,000 | 100,000 | 0.54% | Shares |
| WHI TRUST Co LLC | $396,797 | 97,493 | 0.52% | Shares |
| RAYMOND JAMES FINANCIAL INC | $395,457 | 97,164 | 0.52% | Shares |
| CITADEL ADVISORS LLC | $389,792 | 95,772 | 0.51% | Shares |
| BOOTHBAY FUND MANAGEMENT, LLC | $375,502 | 92,261 | 0.50% | Shares |
| Verdad Advisers, LP | $326,809 | 80,297 | 0.43% | Shares |
| MORGAN STANLEY | $294,367 | 72,326 | 0.39% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $269,349 | 66,179 | 0.36% | Shares |
| BlackRock, Inc. | $221,580 | 54,442 | 0.29% | Shares |
| Fortis Capital Advisors, LLC | $162,800 | 40,000 | 0.21% | Shares |
| Belpointe Asset Management LLC | $162,800 | 40,000 | 0.21% | Shares |
| Pale Fire Capital SE | $161,278 | 39,626 | 0.21% | Shares |
| Squarepoint Ops LLC | $157,814 | 38,775 | 0.21% | Shares |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $132,275 | 32,500 | 0.17% | Shares |
| Stonepine Capital Management, LLC | $122,597 | 30,122 | 0.16% | Shares |
| Connor, Clark & Lunn Investment Management Ltd. | $122,128 | 30,007 | 0.16% | Shares |
| Trexquant Investment LP | $121,030 | 29,737 | 0.16% | Shares |
| STATE STREET CORP | $107,896 | 26,510 | 0.14% | Shares |
| NORTHERN TRUST CORP | $105,165 | 25,839 | 0.14% | Shares |
| Velan Capital Investment Management LP | $101,750 | 25,000 | 0.13% | Shares |
| TWO SIGMA INVESTMENTS, LP | $97,057 | 23,847 | 0.13% | Shares |
| WealthTrust Asset Management, LLC | $83,093 | 20,416 | 0.11% | Shares |
| Independent Advisor Alliance | $73,769 | 18,125 | 0.10% | Shares |
| RBF Capital, LLC | $70,781 | 17,391 | 0.09% | Shares |
| Quadrature Capital Ltd | $67,265 | 16,527 | 0.09% | Shares |
| GOLDMAN SACHS GROUP INC | $65,340 | 16,054 | 0.09% | Shares |
| DIMENSIONAL FUND ADVISORS LP | $64,991 | 15,958 | 0.09% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $57,879 | 14,221 | 0.08% | Shares |
| NANO CAP NEW MILLENNIUM GROWTH FUND L P | $50,875 | 12,500 | 0.07% | Shares |
| Sigma Planning Corp | $41,380 | 10,167 | 0.05% | Shares |
| FMR LLC | $31,770 | 7,806 | 0.04% | Shares |
| Tower Research Capital LLC (TRC) | $10,419 | 2,560 | 0.01% | Shares |
| Steward Partners Investment Advisory, LLC | $9,015 | 2,215 | 0.01% | Shares |
| Vanguard Global Advisers, LLC | $2,951 | 725 | 0.00% | Shares |
| BARCLAYS PLC | $1,233 | 303 | 0.00% | Shares |
| Strengthening Families & Communities, LLC | $1,091 | 268 | 0.00% | Shares |
| BNP PARIBAS FINANCIAL MARKETS | $212 | 52 | 0.00% | Shares |
| JPMORGAN CHASE & CO | $211 | 50 | 0.00% | Shares |
Activists & 5%+ owners 4 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Samsara BioCapital, L.P., Samsara BioCapital GP, LLC, Samsara Opportunity Fund, L.P., Samsara Opportunity Fund GP, LLC, Srinivas Akkaraju ×4 filings | May 22, 2026 | 54.20% | Amendment | · | SEC |
| ElevateBio, LLC (2) | Aug. 5, 2022 | · | Initial filing | · | SEC |
| F2 MG Ltd. (2), F2-TPO Investments, LLC (2), F2 MC, LLC (2), F2 Capital I 2020 LLC (2), F2 Bioscience AV 2022 LLC (2), Globeways Holdings Ltd. (2), Globeways Holdings II Ltd. (2), Morana Jovan-Embiricos (2) | Aug. 5, 2022 | · | Initial filing | · | SEC |
| ElevateBio LLC (2) | Aug. 13, 2020 | · | Initial filing | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 32 insiders · 14 officers · 20 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Andrew Oxtoby | President and Chief Executive Officer | March 19, 2026 A | · | 0 | 0 | $0 |
| Vikas Sinha | Officer Title: President, Chief Financial Officer and Chief Executive Officer | Feb. 21, 2025 S | 49,129 | 0 | 0 | $0 |
| Diana Brainard | Chief Executive Officer | Nov. 19, 2024 S | 723,363 | 0 | 0 | $0 |
| Liisa Ann Bayko | Chief Financial Officer | July 20, 2026 A | · | 0 | 0 | $0 |
| Matthew Gall | Chief Financial Officer | March 19, 2026 A | · | 0 | 0 | $0 |
| Amy O'Leary Vandekop | VP, Corporate Controller | Aug. 27, 2026 A | · | 0 | 0 | $0 |
| Matthew Feinsod | Chief Medical Officer | March 19, 2026 A | 4,030 | 0 | 0 | $0 |
| Brett R Hagen | Chief Accounting Officer | March 19, 2026 A | 0 | 0 | 1 | $-12,869 |
| Edward Miller | General Counsel | Feb. 21, 2025 S | 6,517 | 0 | 0 | $0 |
| Cintia Piccina | Chief Commercial Officer | July 3, 2023 A | 147,000 | 0 | 0 | $0 |
| Ann M. Leen | Chief Scientific Officer | Feb. 2, 2023 A | 124,006 | 0 | 0 | $0 |
| Jeroen B Van Beek | Chief Commercial Officer | Nov. 16, 2022 S | 333,726 | 0 | 0 | $0 |
| Ercem Atillasoy | This Form 4/A is being filed correct the transaction dates reported in the original Form 4 filed on October 24, 2022. Officer T | Oct. 21, 2022 S | 131,372 | 0 | 0 | $0 |
| Agustin Melian | Chief Medical Officer | Oct. 4, 2021 S | 453,529 | 0 | 0 | $0 |
| Laurie Keating | Director | Aug. 1, 2026 A | · | 0 | 0 | $0 |
| Napoleone Ferrara | Director | June 3, 2026 A | 504,000 | 0 | 0 | $0 |
| Michael Dybbs | Director | June 3, 2026 A | · | 0 | 0 | $0 |
| Morana Jovan-Embiricos | Director | June 3, 2026 A | 100,197 | 0 | 0 | $0 |
| David Hallal | Director | June 3, 2026 A | 2,143,662 | 0 | 0 | $0 |
| Anthony P Adamis | Director | June 3, 2026 A | · | 0 | 0 | $0 |
| Srinivas Akkaraju | Director | June 3, 2026 A | 11,444,503 | 0 | 0 | $0 |
| Leone D Patterson | Director | June 3, 2026 A | · | 0 | 0 | $0 |
| Samir Chandrakant Patel | Director | April 10, 2025 A | 100,800 | 0 | 0 | $0 |
| Derek N. Adams | Director | June 6, 2024 A | 70,000 | 0 | 0 | $0 |
| Malcolm Brenner | Director | June 6, 2024 A | 100,197 | 0 | 0 | $0 |
| Juan Vera | Director | June 6, 2024 A | 2,409,928 | 0 | 0 | $0 |
| Shawn Tomasello | Director | June 6, 2024 A | 70,000 | 0 | 0 | $0 |
| Jeffrey S Bornstein | Director | June 6, 2024 A | 110,197 | 0 | 0 | $0 |
| ElevateBio, LLC | Director | July 28, 2022 A | 16,674,766 | 0 | 0 | $0 |
| ANSBERT GADICKE | Director | July 28, 2022 A | 16,674,766 | 0 | 0 | $0 |
| John Robert Wilson | Director | May 25, 2021 A | 3,164,954 | 0 | 0 | $0 |
| Gilead Sciences, Inc. | 10% owner | June 27, 2023 P | 16,635,286 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 5 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| IWC · iShares Trust | 0.01% | 25,753 SH | Sept. 11, 2026 | Daily |
| DCOR · Dimensional ETF Trust | 0.00% | 3,296 NS | July 31, 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0.00% | 137,373 SH | Aug. 19, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 255,337 SH | Aug. 19, 2026 | Daily |
| DFAC · Dimensional ETF Trust | 0.00% | 2,614 NS | July 31, 2026 | N-PORT |
KLRS Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 14 analysts
BUY
Median target
$20.00
+640.7%
6 42.9%
Strong Buy
6 42.9%
Buy
2 14.3%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
7 analysts · 2026-09-30Mean target $18.71 +593.1%
← Below all targets
Current price $2.70
Low$7.00
Mean$18.71
High$25.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| KLRS | $193M | -3.0 | · | · | -65.8% | · |
| INKT | · | -3.8 | 4.5% | -6931.8% | 63.4% | · |
| FRMM | · | · | · | -6881.3% | -368.1% | · |
| ACET | · | -0.5 | · | · | · | · |
| BOLD | $27M | -0.5 | · | · | -46.7% | · |
| CNTB | $159M | -2.8 | -99.8% | -86687.5% | -97.9% | · |
| CLNN | $64M | · | -41.5% | -13086.5% | 200.2% | · |
| EXOZ | $92M | -10.0 | · | · | -172.3% | · |
| XLO | $3M | -0.2 | 589.9% | -80.0% | -165.5% | · |
| INMB | $41M | -0.8 | 257.1% | -91866.0% | -175.3% | · |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 11, 2026